STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Tango Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 5,905,349 shares of Tango Therapeutics common stock, equal to 5.45% of the company’s outstanding shares based on an 108,394,190 share count used in the filing. The reported position shows shared voting and dispositive power of 5,905,349 shares and no sole voting or dispositive power.

The filing is submitted on Schedule 13G and states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Positive
  • Material disclosed stake: Reporting Persons beneficially own 5,905,349 shares (5.45%), exceeding the 5% reporting threshold.
  • Passive classification: The filing is on Schedule 13G and states the securities are held in the ordinary course of business and not to change control.
Negative
  • No sole voting or dispositive power is reported, indicating the Reporting Persons do not control voting decisions for the shares.

Insights

TL;DR: Adage holds a material passive stake (5.45%) in Tango, signaling meaningful investor interest without control intent.

Adage’s disclosed 5,905,349-share position represents a material ownership level above the 5% reporting threshold and is calculated against 108,394,190 shares outstanding as referenced in the filing. The filing under Schedule 13G and the explicit certification that the securities are held in the ordinary course indicate a passive investment stance rather than an active campaign for control. For market participants, this confirms institutional attention while maintaining the company’s existing governance structure.

TL;DR: The reporters disclose only shared voting/dispositive power and assert passive intent, so governance control is not indicated.

The statement shows no sole voting or dispositive power and only shared authority over the 5.45% stake. The Schedule 13G classification and the certification language reduce the likelihood that this holding will be treated as an attempt to influence board composition or corporate control. That said, a >5% passive stake can still prompt issuer engagement; the filing itself contains no indication of activist intent or proposed governance actions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

Who filed the Schedule 13G for Tango Therapeutics (TNGX)?

The filing was made by Adage Capital Management, L.P. and individuals Robert Atchinson and Phillip Gross as Reporting Persons.

How many Tango Therapeutics (TNGX) shares were reported?

The filing reports beneficial ownership of 5,905,349 shares of common stock.

What percent of Tango Therapeutics does the reported stake represent?

The reported position represents 5.45% of the outstanding common stock, based on 108,394,190 shares used in the filing's calculation.

Do the filers have voting or dispositive power over the shares?

The filers report no sole voting or dispositive power and instead report shared voting and shared dispositive power for 5,905,349 shares.

Is the position reported as passive or activist?

The Schedule 13G includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control, indicating a passive position.
Tango Therapeutics Inc

NASDAQ:TNGX

TNGX Rankings

TNGX Latest News

TNGX Latest SEC Filings

TNGX Stock Data

1.06B
126.97M
12.26%
109.5%
22.83%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON